Latest Breakthrough nod goes to Novartis

Share this article:

The FDA announced Tuesday that it has approved the Novartis lung cancer drug Zykadia, or ceritinib (previously known as LDK378).

The approval is for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), specifically those who were previously treated with Pfizer's Xalkori (crizotinib). Xalkori is the only other approved ALK tyrosine kinase inhibitor but one which (like many molecular targeted drugs) encounters resistance.

The approval is the fourth drug with the FDA's Breakthrough Therapy designation to be approved by the agency.

The drug is also considered an orphan product and is notable for its approval speed: the approval deadline was August 24, four months from now.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.